Role of tumor heterogeneity in drug resistance
Journal Title: Global Journal of Cancer Therapy - Year 2017, Vol 3, Issue 1
Abstract
Cancer is a leading cause of death in men worldwide and the major cause of cancer related death is drug resistance [1,2]. In past few years, scientists have established tumor heterogeneity as a phenomenon of critical importance in the natural history of individual neoplasms and drug resistance [3-5]. The concept of tumor heterogeneity has a major impact on therapeutic approaches [6-9]. Drug resistance creates difficulty in cancer treatment and is directly linked to the tumor progression and poorer prognosis.
Authors and Affiliations
Kumar Dhruv
Keywords
Related Articles
- EP ID EP353666
- DOI 10.17352/2581-5407.000020
- Views 77
- Downloads 0
Genetic Polymorphisms and Cisplatin- Related Nephrotoxicity
Cisplatin is one of the most widely applied antineoplastic agents used to treat different types of solid tumours. However, its use is limited by serious side- effects including nephrotoxicity. Cisplatin accumulates in pr...
The Paradoxes of Neoantigenes in Predicting Better Prognosis of Cancer Patients
Increased neoantigens of cancer generated by mutations are reported to be associated with favorable prognosis of cancer patients. The interesting findings contradict the notions that cancers were caused by accumulation o...
The Role of Decavanadate in Anti-Tumour Activity
Decavanadate compounds were described to be involved in a variety of biological activities and responses such as anti-virus, anti-bacterial and anticancer. While the mechanisms of action of the anti-viral and anti-bacter...
The Promise of Disease Management in Greece
Background: Disease Management (DM) is an approach to health care that coordinates resources across the entire health care delivery system and throughout the course of a disease. Objectives: The purpose of the present s...
MEK Inhibitors in Combination with Immune Checkpoint Inhibition: Should we be Chasing Colorectal Cancer or the KRAS Mutant Cancer
In the past few years, immunotherapy, particularly immune checkpoint inhibitors, have redefined standard of care cancer treatment for numerous malignancies. However, despite the wealth of promising data and great enthusi...